logo

ONC

Beone Medicines·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ONC fundamentals

Beone Medicines (ONC) released its earnings on Nov 6, 2025: revenue was 1.41B (YoY +40.77%), beat estimates; EPS was 2.65 (YoY +3044.44%), beat estimates.
Revenue / YoY
1.41B
+40.77%
EPS / YoY
2.65
+3044.44%
Report date
Nov 6, 2025
ONC Earnings Call Summary for Q3,2025
  • BRUKINSA leadership: $1.1B Q3 revenue, 51% growth, solidifying global BTK dominance.
  • Sonro breakthrough: 74% 6-year PFS vs. 62% for competitors, FDA Breakthrough Designation in MCL.
  • CDAC advantage: 86% ORR, 79% 12-month PFS vs. 62% for competitors in CLL Phase III.
  • ZS combo dominance: 92% uMRD at 1 year vs. 32% for AV, 4x faster MRD achievement.
EPS
Revenue

Revenue & Expenses

ONC has released its 2025 Q3 earnings report, with revenue of 1.41B, reflecting a YoY change of 41.00%, and net profit of 124.84M, showing a YoY change of 202.88%. The Sankey diagram below clearly presents ONC's revenue sources and cost distribution.

Key Indicators

Beone Medicines (ONC) key financial stats and ratios, covering profitability, financial health, and leverage.
Beone Medicines (ONC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Beone Medicines (ONC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Beone Medicines (ONC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Beone Medicines (ONC) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Beone Medicines (ONC) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield